Who We Are

About Us

Fulhold Pharma Limited (UK) (Fulhold) is the ultimate owner of CarboHydrate Derived Fulvic Acid (CHD-FA), a patented molecular technology platform. The compound has powerful and broad-based activities in a wide range of applications.

Fulhold produces CHD-FA using a sustainable, environmentally-friendly technology, the process of which is protected by a comprehensive suite of patents. Its powerful broad-spectrum activity makes CHD-FA an effective agent in the fight against antimicrobial resistance. Given its novel and synergistic mechanisms of action, the use of CHD-FA is advantageous as it reduces the use (and therefore over-use) of more specific but more limited spectrum antimicrobials.

Founded as FulHold Ltd in 2002, Fulhold Pharma Limited has a proven track record of the production and supply worldwide of pure CHD-FA together with a range of formulated products using CHD-FA as the platform technology.

‘Platform Technology’ is a term for technology that enables and reduces the time, effort and cost of developing multiple applications using the same ‘platform’.

CHD-FA is a novel platform technology and the base active ingredient in many current and planned formulations for application in the pharmaceutical, cosmetic and agricultural industries.

CHD-FA is a safe, non-toxic, water-soluble and heat-stable ingredient that is manufactured to GMP standards. It is a new, pure, uniform version of an ancient ingredient from nature – environmental Fulvic Acid. Environmental Fulvic Acid is derived from the microbial breakdown of plant and animal matter and has been present in the environment for millions of years.

CHD-FA, however, is a pure form of Fulvic Acid but without environmental contaminants such as heavy metals, herbicide and pesticide residues. It is a safer and more effective form of Fulvic Acid than that sourced from the environment.

Reliable evidence of its proven safety and toxicity data means that CHD-FA can provide a platform technology for a wide range of applications at vastly reduced timeframes and cost.

Key People

David Squire
Allan Vickers
Hans Wedermann
Stephen Leivers
Kenneth Strickland
Theo De Regibus

Key Senior Management
Stefan Coetzee
Stewart Clark

  • Our journey started when the company tested Oxy-Fulvic Acid in vitro at the University of Cape Town (UCT) on the Vaccinia Virus.
  • Several observational studies were then conducted in conjunction with HIV-positive patients (under their physicians’ observation) with good results.
  • We acquired 124 Global Fulvic & Humic Acid patents from Enerkom in South Africa.
  • Merged with Oxytech to produce the world’s first Carbohydrate Derived Fulvic Acid (CHD-FA).
  • Launched BioBalance range with ATKA in South Africa – eventually sold to Ascendis.
  • HIV Clinical Trial conducted in India.
  • Provisional work started by the U.S. Department of Defense – “Evaluation of Carbohydrate Derived Fulvic Acid (CHD-FA) as a Topical Broad-Spectrum Antimicrobial for Drug Resistant Wound Infections”.
  • Fulhold was listed on the GXG Exchange in April 2015 (GXG was a Danish based exchange which shut down August 2015). The principal reasons were to raise capital and as a stepping stone to the company’s ambition of a future listing on the AIM in London or the LSE (both more expensive options and not really suitable at the time). The process was useful in that it enabled Fulhold to streamline its structures.
  • Bought out the shares in Oxytech.
  • Approval received for a 3 year wound treatment study funded by the U.S. Department of Defense.
  • FulviDoc (Pty) Ltd was registered to produce and market Animal Health products in South Africa.
  • Registered 6 Animal Health products under Act 36 in South Africa.
  • Fulderm Sweden registered Reczema (an eczema cream) as a Medical Device in the EU.
  • GMP license awarded to Fulvimed SA for the manufacture of CHD-FA as an API.
  • Fulderm International Ltd (UK) and Fulhold Inc (USA) were registered and started the process to register CHD-FA as an Atopic Dermatitis (eczema) cream with the US FDA.
  • In response to the Covid pandemic, CHD-FA was tested as a sanitiser at BluTest Laboratories Ltd in Scotland, demonstrating the product was effective against all enveloped viruses as defined in EN 14476:2013 + A2:2019. This includes all coronaviruses and SARS‐CoV‐2.
  • Sought USA FDA Pre-IND advice and received a favourable response to Fulhold’s plans to develop, trial and launch a CHD-FA cream for Atopic Dermatitis.
  • Atopic Dermatitis Phase 2a Clinical Trial started in South Africa.
  • Started Broiler trial at the University of Stellenbosch – the trial will comprise the testing of CHD-FA as a feed additive for broiler production. It is believed that the use of CHD-FA will result in increased growth and decreased mortality through actions associated with the maintenance or improved gut health and the microbiome.